Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts
- 27 February 2018
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (8), 776-778
- https://doi.org/10.1001/jama.2017.21897
Abstract
In December 1993, the US Food and Drug Administration (FDA) granted approval for gabapentin, under the brand name Neurontin, for adjunctive therapy of partial sThis publication has 10 references indexed in Scilit:
- Gabapentin for Chronic Neuropathic PainJAMA, 2018
- Gabapentinoid Use in the United States 2002 Through 2015JAMA Internal Medicine, 2018
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016
- Association of Off-label Drug Use and Adverse Drug Events in an Adult PopulationJAMA Internal Medicine, 2016
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012JAMA, 2014
- Gabapentin add-on for drug-resistant partial epilepsyCochrane Database of Systematic Reviews, 2013
- Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigationTrials, 2012
- The Neurontin Legacy — Marketing through Misinformation and ManipulationNew England Journal of Medicine, 2009
- Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry DocumentsAnnals of Internal Medicine, 2006
- Off-label Prescribing Among Office-Based PhysiciansArchives of Internal Medicine, 2006